CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of ...

June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161- -This follows another recent authorization by Anthem ...

NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation ...

PoNS Therapeutic Experience Program (PoNSTEP) study demonstrates durable long-term beneficial effects of PoNS Therapy® on gait deficit improvement in people with Multiple Sclerosis- -Presentation of ...

Helius Medical Technologies (HSDT) stock surged on Wednesday after the neurotech company announced an authorized claim for payment for its Portable Neuromodulation Stimulator (PoNS) from CVS Health ...

NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic ...

(RTTNews) - Helius Medical Technologies (HSDT) announced an authorized claim for payment for the PoNS Device from Aetna Healthcare. The out-of-network price, which typically is 30 to 40% below in ...

ByInvesting.com • May 02, 2025 HSDT stock touches 52-week low at $0.26 amid sharp annual decline Helius Medical Technologies Inc. (NASDAQ:HSDT) stock has reached a new 52-week low, trading at $0.26.